Loading...

Indiana's Pharmaceutical Manufacturing Boom Creates New IIoT Opportunities

Industrial IoT (IIoT)

Published by IOT Indiana Research & Editorial Team

Indiana's Pharmaceutical Manufacturing Boom Creates New IIoT Opportunities

Indiana has long been a pharmaceutical state, thanks mainly to Eli Lilly, but the scale of current investment is changing the business picture for everyone nearby. Lilly alone has described more than $21 billion of its domestic manufacturing commitments as allocated to Indiana, according to reporting on its recent announcements, and other biopharma and life sciences operations are expanding across Indianapolis, Bloomington and the LEAP district in Lebanon.

This article is written for suppliers, integrators and plant engineers rather than investors. It looks at how pharmaceutical manufacturing buys industrial IoT, which products and services fit, what barriers to entry exist, and how a small Indiana company can prepare. For a closer look at what Lilly itself is building, see our companion piece on Lilly's Lebanon sites and connected manufacturing.

The boom in context

Lilly has said it is building facilities in Lebanon for genetic medicine, active ingredients and a research and clinical manufacturing "Medicine Foundry." It has also described a roughly $27 billion national manufacturing plan announced in 2025, with nearly 10,000 construction jobs and more than 3,000 permanent jobs for engineers, scientists and other staff associated with that plan. Lilly also says it accounts for about 70 percent of Indiana's pharmaceutical economic output, a figure that comes from the company and shows how concentrated the sector is.

Concentration matters. A state whose pharmaceutical sector depends heavily on one company has a smaller buyer pool than a state with many mid-size drugmakers. For suppliers, that means winning work depends on understanding the dominant customer's procurement style, and on building relationships with the engineering firms and contract manufacturers around it.

How pharma buys differently

FactorTypical industrial buyerPharmaceutical buyer
Purchase driverCost, uptimeCompliance, batch integrity, then cost
Change speedWeeksMonths, with formal change control
DocumentationManuals and datasheetsValidation packages, audit trails, traceable certificates
Software updatesFrequent, often automaticControlled, tested and approved before release
Supplier assessmentReference checksQuality audits and questionnaires
Sales cycleShort to mediumLong, with multiple approvals

The practical lesson: slow does not mean unprofitable. Pharmaceutical facilities keep equipment for many years, support it with long maintenance contracts, and pay for reliability. A supplier that clears the qualification hurdle once can serve a plant for a decade.

Seven IIoT opportunity areas

1. Environmental and cleanroom monitoring

Plants need continuous records of temperature, humidity, pressure differentials and particle counts. Wireless sensors with validated software can simplify retrofits in warehouses, stability chambers and non-sterile areas, though aseptic areas generally require stricter, engineered solutions.

2. Cold storage and cold chain visibility

Many biologics need refrigerated or frozen storage and transport. Data loggers, real-time location and temperature sensing, and excursion alerts with documented response workflows create value in Indiana's warehouses and trucking operations.

3. Utilities monitoring

Purified water, water for injection, clean steam, compressed air, nitrogen and chilled water all have quality attributes that must be proven. Conductivity, TOC, flow, temperature and pressure sensors, plus trending and alarm management, are standard needs.

4. Condition monitoring for critical equipment

Pumps, compressors, air handlers, chillers and filling line mechanics benefit from vibration and temperature monitoring. Because unplanned downtime can ruin a batch, predictive maintenance has a clear business case. Our article on predictive maintenance in Indiana describes how to choose which assets to start with.

5. Energy and sustainability metering

Large pharma sites use a lot of energy and increasingly report on emissions. Sub-metering for steam, electricity and chilled water gives plants a basis for efficiency projects and reporting. Meter selection should consider accuracy, calibration and data access.

6. Data connectivity and historians

Plants need middleware that collects data from many vendors' equipment into a central historian and passes the right information to quality and execution systems. OPC UA, MQTT and standards-based gateways are common building blocks, along with careful network segmentation.

7. Asset tracking and tool management

Tracking portable equipment, calibration status and consumables reduces errors. Barcodes, RFID and real-time location systems can link equipment to batch records and calibration due dates.

Barriers and how to clear them

Validation expertise

Many technology vendors fail not because their products are weak, but because they cannot supply validation documentation. Learn what a validation master plan contains, how installation, operational and performance qualification work, and what a traceability matrix is. Build standard documentation templates for your products.

Quality system maturity

Suppliers are audited. Maintain controlled documents, training records, corrective action procedures and complaint handling. ISO 9001 certification helps, and some customers will look for more specific alignment with GMP expectations for suppliers.

Cybersecurity

Pharma IT and quality teams scrutinize remote access, user management, logging and patching. Expect questionnaires. Maintain a security whitepaper and a patch policy that fits validated environments, where updates are staged and documented.

Data integrity design

Products should provide role-based access, unique user accounts, protected audit trails, time synchronization and secure data export. Retrofitting these features after a product is on the market is expensive.

A preparation plan for a small Indiana company

  1. Quarter 1: Learn the language. Study GMP basics, 21 CFR Part 11 and the idea of validated systems. Talk to a quality professional who has worked in a drug plant.
  2. Quarter 1 to 2: Audit your documentation. Compare your manuals, change records and test procedures with what a pharma auditor would expect.
  3. Quarter 2: Build one validation-ready package. For example, a monitoring system for a storage warehouse, with installation instructions, test protocols and sample reports.
  4. Quarter 3: Pilot in a lower-risk space. Warehouses, utilities rooms and non-product-contact areas are common starting points.
  5. Quarter 4: Publish a case study. Document results, including problems and fixes, with the customer's permission.
  6. Ongoing: Maintain relationships. Attend life sciences events, speak with engineering firms working on regional projects and join industry groups.

An illustrative cold chain business case

These numbers are hypothetical. A regional pharmaceutical distributor operates a 60,000 square foot temperature-controlled warehouse and a fleet of twelve refrigerated trucks. Today it uses manual temperature checks and a handful of standalone loggers.

  • The company installs networked temperature and humidity sensors in warehouse zones, adds telematics-linked sensors on trucks, and sets alerts that notify supervisors within minutes of an excursion.
  • Over a year, the system detects a failing refrigeration unit and several door-open events. Technicians respond before product leaves its allowed range.
  • The distributor avoids a single rejected shipment valued at several hundred thousand dollars, and its customers receive automatically generated temperature reports for audits.

The cost of the system may be a fraction of the loss avoided. The more valuable effect is credibility: a distributor that can prove control wins contracts that a competitor with paper logs cannot.

Packaging your offer so a quality team can approve it

Pharmaceutical buyers prefer clearly bounded offers. A proposal that says "we will monitor your plant" is hard to approve. One that says "we will supply, install and document temperature and humidity monitoring for Warehouse B, with installation qualification and a monthly calibration service" is easy to evaluate.

  • Define the scope in one page. List the areas covered, the measurements, the alarm limits and who responds.
  • Include the paperwork. Offer installation and test protocols, calibration certificates traceable to recognized standards, and a change history.
  • Price the lifecycle. Show first-year cost and annual cost for calibration, software support and spares.
  • State response times. Say how quickly you respond to an alarm or failure, in hours.
  • Offer a pilot with exit criteria. A time-limited pilot with agreed success measures reduces perceived risk.

Choosing a first customer

The best first pharma customer is not always the biggest. Contract manufacturers, specialty distributors, university research facilities and mid-size biotech companies often move faster than global leaders and still demand documented quality. A success there becomes the reference that opens conversations with larger firms. Whichever customer you choose, agree up front on what you may say publicly, because many pharmaceutical companies restrict how suppliers describe their work.

Workforce and the hidden constraint

Every opportunity above depends on people who understand both technology and regulated manufacturing. Indiana's universities and technical colleges produce engineers and technicians, but demand from large employers is steep. Smaller firms will compete for the same people. Training junior staff in documentation discipline, instrument basics and cybersecurity hygiene, and pairing them with experienced mentors, often works better than trying to hire fully formed specialists.

Programs that support manufacturers include Purdue Manufacturing Extension Partnership, Conexus Indiana and the Next Level Manufacturing Institute. State grant programs change over time; the Manufacturing Readiness Grants, for instance, were paused in 2025, so confirm current availability before planning around one.

Risks to keep in view

  • Customer concentration. Dependence on a few large buyers can squeeze margins and create abrupt changes in demand.
  • Regulatory and pricing pressure. Changes in drug pricing, trade policy or demand for specific medicines can shift investment plans.
  • Project timing. Plants reach operation later than planned, and supplier spending ahead of confirmed demand can strand resources.
  • Talent competition. Higher wages in life sciences may strain other manufacturers.

The bottom line

Indiana's pharmaceutical boom is not a gold rush for quick sellers. It rewards companies that treat documentation, validation and data integrity as part of the product. Those that invest in those capabilities can win long, stable relationships in environmental monitoring, utilities, cold chain, condition monitoring and data integration. Start small, build a clean reference, and let proven reliability open the next door.

Frequently asked questions

Reporting on Eli Lilly's announcements points to large investments in active ingredient, genetic medicine and R&D manufacturing, including facilities in the LEAP district in Lebanon. Lilly has said more than $21 billion of its domestic commitments is allocated to Indiana, and other biopharma operations are expanding as well.

Common categories include environmental and cleanroom monitoring, cold chain sensors and loggers, utilities monitoring for water, steam and gases, condition monitoring for critical equipment, energy sub-metering, data connectivity software and asset tracking, all with strong audit trail and security features.

Validation is the documented process of proving that a system does what it is intended to do, usually through installation, operational and performance qualification. Suppliers who can provide ready-made validation documentation reduce the buyer's workload and are more likely to be selected.

Sales cycles are typically longer than in other industries because of quality audits, security reviews and formal change control. Starting with lower-risk areas such as warehouses and utilities, and building a documented reference, can shorten later cycles.

Purdue Manufacturing Extension Partnership, Conexus Indiana and the Next Level Manufacturing Institute offer guidance and training. State grants change over time, and the Manufacturing Readiness Grants were paused in 2025, so verify current availability.

Key risks are reliance on a small number of large buyers, delays or changes in project timing, regulatory or pricing shifts, and competition for skilled workers. Staged investment and diversification into other regulated industries can reduce exposure.

Related articles

Top